Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Castle Creek (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Castle Creek (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2025
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Agreements        
Long-term royalty and commercial payment receivables under the cost recovery method   $ 59,916   $ 55,936
Short-term royalty and commercial payment receivables under the cost recovery method   413   $ 413
Payments of consideration under RPAs, AAAs and CPPAs   8,000 $ 15,000  
Fair value of warrants   605    
Royalty Financing Transaction | Castle Creek Biosciences, Inc        
Agreements        
Rights entity acquired as a percentage of specified percentage 6.70%      
Percentage of domestic sales 8.75%      
Percentage of worldwide sales 8.00%      
Percentage of proceeds from potential PRV 20.00%      
Number of warrants received | shares 10,464      
Exercise price of warrants received (in dollars per share) | $ / shares $ 215.03      
Term of warrants received 10 years      
Aggregate purchase price $ 5,000      
Long-term royalty and commercial payment receivables under the cost recovery method 4,400      
Allowance for credit losses   $ 0    
Fair value of warrants $ 600      
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Volatility        
Agreements        
Derivative Asset, Measurement Input 1.28      
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Risk-free interest rate        
Agreements        
Derivative Asset, Measurement Input 0.042